 |
|
|
| |
48-Week Efficacy of Dolutegravir Relative to Commonly Used 3rd Agents in Treatment-Naive HIV-1-Infected Patients: A Systematic Review and Network Meta-analysis
|
| |
| |
Reported by Jules Levin
14th European AIDS Conference Oct 16-19 2013 Brussels, Belgium
Dipen A. Patel,1 Sonya J. Snedecor,1 Wing Yu Tang,1 Lavanya Sudharshan,1 Jessica W. Lim,2 Robert Cuffe,3 Sonia Pulgar,4 Kim A. Gilchrist,5 Rodrigo Refoios Camejo,6 Jennifer Stephens,1 Garrett Nichols7
1Pharmerit International, Bethesda, MD, USA; 2GlaxoSmithKline, Stockley Park, UK; 3ViiV Healthcare, Middlesex, UK; 4Becton Dickinson, Franklin Lakes, NJ, USA (GSK employee at time of research); 5-7GlaxoSmithKline, 5Renaissance, PA, USA; 6Brentford, UK; 7Research Triangle Park, NC, USA
|
| |
|
|
|
|
|
